NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT03959527,Zoliflodacin in Uncomplicated Gonorrhoea,https://clinicaltrials.gov/study/NCT03959527,,COMPLETED,"This trial is a multi-center, open label, randomized controlled, non-inferiority phase III trial evaluating the safety and efficacy of a 3 g oral dose of zoliflodacin compared to a combination of a single intra-muscular 500 mg dose of ceftriaxone and a single 1 g oral dose of azithromycin for the treatment of uncomplicated gonorrhoea.",YES,Gonorrhea,DRUG: zoliflodacin|DRUG: ceftriaxone|DRUG: azithromycin,"Microbiological Cure Rate for Zoliflodacin Compared to a Combination of a Single Dose of Ceftriaxone and Azithromycin., Proportion of participants with microbiological cure as determined by culture at urethral or cervical sites at test of cure visit in micro-ITT (urogenital) analysis set, Day 6 (+/- 2)","Safety of a Single Dose of Zoliflodacin Will be Assessed Compared to a Combination a Single Dose of Ceftriaxone and Azithromycin., Incidence, severity, causality and seriousness of treatment-emergent adverse events (including clinically significant abnormal laboratory values/procedures i.e., physical examination per protocol), Day 30|Microbiological Cure Rate of Pharyngeal Gonorrhoea Will be Determined After Administration of a Single Dose of Zoliflodacin Compared to a Combination of a Single Dose of Ceftriaxone and Azithromycin., Proportion of participants with microbiological cure as determined by culture at pharyngeal sites at test of cure visit in micro-ITT (Pharyngeal)., Day 6|Microbiological Cure Rate of Rectal Gonorrhoea Will be Determined After Administration of a Single Dose of Zoliflodacin Compared to a Combination of a Single Dose of Ceftriaxone and Azithromycin., Proportion of participants with microbiological cure as determined by culture at rectal sites at test of cure visit in micro-ITT (Rectal)., Day 6|The Clinical Cure Rate of Symptomatic Gonorrhoea in Male Participants Will be Determined After Administration of a Single Dose of Zoliflodacin Compared to a Combination of Single Dose of Ceftriaxone and Azithromycin., Proportion of male participants with clinical cure at test of cure visit in Clinical Cure Population., Day 6|Microbiological Cure Rate of Urogenital Gonorrhoea Among Women, After Administration of a Single, Oral, 3 g Dose of Zoliflodacin Compared to a Combination of a Single IM 500 mg Dose of Ceftriaxone and a Single 1 g Oral Dose of Azithromycin, Proportion of female participants with microbiological cure as determined by culture at cervical or urethral site at TOC in micro-ITT (Urogenital) population, Day 6|Microbiological Cure Rate of Urogenital Gonorrhoea Among Men, After Administration of a Single, Oral, 3 g Dose of Zoliflodacin Compared to a Combination of a Single IM 500 mg Dose of Ceftriaxone and a Single 1 g Oral Dose of Azithromycin, Proportion of male participants with microbiological cure as determined by culture at urethral site at TOC in micro-ITT population, Day 6|Antimicrobial Susceptibility Profile Will be Determined of Gonococcal Strains Isolated From Participants With Uncomplicated Gonorrhoea at Baseline and the Test of Cure Visit., Antimicrobial susceptibility profile of gonococcal strains isolated at baseline and at test of cure visit., Day 6|The Proportion of Participants With Eradication of NG NAAT at TOC Will be Determined From Urogenital Specimens After Administration of a Single Dose of Zoliflodacin Compared to a Combination of a Single Dose of Ceftriaxone and Azithromycin., Proportion of participants with a positive NG NAAT result from urethral or cervical sites at baseline and a negative NG NAAT result at test of cure visit in micro-ITT analysis set., Day 6|Proportion of Participants With Eradication of NG NAAT at TOC Determined From Pharyngeal Specimens After Administration of a Single Dose of Zoliflodacin Compared to a Combination of a Single Dose of Ceftriaxone and Azithromycin., Proportion of participants with a positive NG NAAT at baseline from pharyngeal sites and a negative NG NAAT at test of cure visit in micro-ITT analysis set., Day 6|Proportion of Participants With Eradication of NG NAAT at TOC Determined From Rectal Specimens After Administration of a Single Dose of Zoliflodacin Compared to a Combination of a Single Dose of Ceftriaxone and Azithromycin., Proportion of participants with a positive NG NAAT from rectal sites at baseline and a negative NG NAAT at test of cure visit in micro-ITT analysis set., Day 6|Arithmetic Mean Plasma Concentration of Zoliflodacin, Arithmetic mean plasma concentration (ng/mL) of zoliflodacin following oral administration of single oral dose of zoliflodacin 3 g, 15 min - 1 hour|Arithmetic Mean Plasma Concentration of Zoliflodacin, Arithmetic mean plasma concentration (ng/mL) of zoliflodacin following a single oral dose administration of zoliflodacin 3 g, 2-2.5 h|Arithmetic Mean Plasma Concentration of Zoliflodacin, Arithmetic mean plasma concentration (ng/mL) of zoliflodacin following administration of a single oral dose of zoliflodacin 3 g, 4.5 - 5h|Arithmetic Mean Plasma Concentration of Zoliflodacin, Arithmetic mean plasma concentration (ng/mL) of zoliflodacin following administration of a single oral dose zoliflodacin 3 g, 10 -12 h|Arithmetic Mean Plasma Concentration of Zoliflodacin, Arithmetic mean plasma concentration (ng/mL) of zoliflodacin following administration of a single oral dose of zoliflodacin 3 g, 24 - 36 h|Evaluation of the Plasma PK Profile After a Single, Oral, 3 g Dose of Zoliflodacin, Geometric mean time to maximum plasma concentration (Tmax) after a single, oral, 3 g dose of zoliflodacin, Day 2|Evaluation of the Plasma PK Profile After a Single, Oral, 3 g Dose of Zoliflodacin, Geometric mean time to last (Tlast) plasma concentration above the lower limit of quantitation, Day 2|Evaluation of the Plasma PK Profile After a Single, Oral, 3 g Dose of Zoliflodacin, Geometric mean maximum plasma concentration (Cmax) after a single, oral 3 g dose of zoliflodacin, Day 2|Evaluation of the Plasma PK Profile After a Single, Oral, 3 g Dose of Zoliflodacin, Geometric mean plasma area under the concentration-time curve (AUC0-last) from time zero to the last concentration above lower level of quantification, Day 2",,Global Antibiotics Research and Development Partnership,,ALL,"CHILD, ADULT, OLDER_ADULT",PHASE3,1011,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,STI_Zoli001|2019-000990-22,2019-11-06,2023-08-30,2023-09-18,2019-05-22,2024-07-26,2024-07-26,"Jefferson County Department of Health, Birmingham, Alabama, 35233, United States|University of Alabama at Birmingham, Birmingham, Alabama, 35294-0006, United States|San Francisco Department Of Public Health City Clinic, San Francisco, California, 94103, United States|Bell Flower Clinic, Indianapolis, Indiana, 46202, United States|Louisiana State University Health Sciences Center, New Orleans, Louisiana, 70112, United States|Public Health - Seattle & King County STD Clinic, Seattle, Washington, 98104, United States|Institute of Tropical Medicine, Antwerp, 2000, Belgium|Public Health Service (GGD) Amsterdam / STI Outpatient Clinic, Amsterdam, 1018 WT, Netherlands|SAMRC Botha's Hill Clinical Research Site, Bothas Hill, 3660, South Africa|Masiphumelele Research Site, Cape Town, 7975, South Africa|Ndlovu Research Centre, Elandsdoorn, 0470, South Africa|Wits RHI, Johannesburg, 2001, South Africa|Setshaba Research Centre, Soshanguve, 0152, South Africa|SAMRC Tongaat Clinical Research Site, Tongaat, 4400, South Africa|Bangrak STI Center, Bangkok, 10120, Thailand|Institute of HIV Research and Innovation, Bangkok, 10330, Thailand|Silom Community Clinic, Bangkok, 10400, Thailand","Study Protocol, https://cdn.clinicaltrials.gov/large-docs/27/NCT03959527/Prot_000.pdf|Statistical Analysis Plan, https://cdn.clinicaltrials.gov/large-docs/27/NCT03959527/SAP_001.pdf|Informed Consent Form, https://cdn.clinicaltrials.gov/large-docs/27/NCT03959527/ICF_003.pdf"
